Abstract
BACKGROUND AND PURPOSE: The yield of DSA in patients with SAH and negative initial noninvasive neurovascular examinations (CTA or MRA) is not well-understood. This study aimed to determine the yield of DSA for the detection of causative vascular lesions in this clinical scenario.
MATERIALS AND METHODS: We examined the yield of DSA for the detection of causative vascular lesions in a cohort of patients presenting to our institution with SAH and negative initial noninvasive neurovascular examinations during a 5-year period. Two experienced neuroradiologists independently evaluated the NCCT to determine the SAH pattern (diffuse, perimesencephalic, or peripheral sulcal) and the catheter angiograms to assess the presence of a causative vascular lesion.
RESULTS: Fifty-five patients were included in the study, with a mean age of 58.2 years (median, 58 years; range, 25–88 years). Twenty-eight patients were men (50.9%), and 27 were women (49.1%). The initial noninvasive examination was a CTA in 47 patients (85.5%) and an MRA in 8 patients (14.5%). Thirty-three patients had diffuse SAH (60%); 11, perimesencephalic SAH (20%); and 11, peripheral sulcal SAH (20%). DSA demonstrated a causative vascular lesion in 6 patients (10.9%), 5 of whom had diffuse SAH (yield of 15.2%) and 1 of whom had peripheral sulcal SAH (yield of 9.1%). No causative vascular lesions were found in patients with perimesencephalic SAH.
CONCLUSIONS: DSA is a valuable tool in the evaluation of patients with diffuse and peripheral sulcal SAH who have negative initial noninvasive neurovascular examinations, demonstrating a causative vascular lesion in 15.2% and 9.1% of patients, respectively.
ABBREVIATIONS:
- CI
- confidence interval
- DAVF
- dural arteriovenous fistula
Nontraumatic SAH affects approximately 20,000–30,000 people in the United States each year1 and carries up to 45% thirty-day mortality as well as poor functional outcome among survivors.2⇓⇓–5 Although most cases of SAH are caused by ruptured cerebral aneurysms,4 prior studies have shown that in 5%–36% of cases, the initial neurovascular examination does not reveal a causative cerebral aneurysm or other vascular abnormality.6⇓⇓⇓⇓⇓⇓⇓⇓⇓⇓⇓⇓⇓⇓⇓⇓⇓⇓⇓⇓⇓⇓⇓⇓–31 Prompt identification of patients who have a vascular abnormality as the cause of SAH despite negative initial neurovascular examinations is important because instituting treatment may avert rehemorrhage leading to increased morbidity and mortality.3
In recent years, advances in CTA and MRA have allowed these techniques to become valuable noninvasive alternatives to DSA for the evaluation of patients with SAH, with some institutions advocating CTA as the primary means of diagnosis in this patient population.29,32,33 However, DSA continues to be the criterion standard for the evaluation of patients with SAH and remains the primary means of diagnosis at many centers.34,35
Most prior studies have examined the yield of repeat DSA in patients with SAH who have a negative initial DSA study, which has varied widely from 0% to 36%.6,7,10⇓⇓⇓–14,16⇓⇓–19,21⇓⇓⇓⇓⇓⇓–28,30,31 To date, only 1 study has examined the yield of DSA in patients with a negative initial CTA, which was 10% in patients with diffuse SAH, 17% in patients with peripheral sulcal SAH, and 0% in patients with perimesencephalic SAH.29
The present study aimed to determine the yield of DSA for the detection of causative vascular lesions in a cohort of patients with SAH who had negative initial noninvasive neurovascular examinations (CTA or MRA).
Materials and Methods
Patient Selection and Study Protocol
Our study was approved by the institutional review board of our hospital and was conducted in compliance with the Health Insurance Portability and Accountability Act. We conducted a retrospective review of prospectively collected data of patients who presented to our institution from January 1, 2007, until December 31, 2011, with nontraumatic SAH evidenced by NCCT of the head or CSF xanthochromia and an initial CTA or MRA that was negative for a causative vascular abnormality. According to our institutional protocol, we performed DSA of the intracranial circulation within 24 hours of the initial noninvasive neurovascular examination; if the findings were negative, a repeat DSA examination was performed 7 days after presentation to identify a causative vascular etiology for the SAH.
Image Acquisition
NCCT acquisitions were performed according to standard protocols on 16- (LightSpeed) or 64-section helical CT scanners (Discovery HD; GE Healthcare, Milwaukee, Wisconsin). CTA acquisitions were performed on 16- (LightSpeed) or 64-section helical CT scanners (Discovery HD) by scanning from the base of the C1 vertebral body to the vertex by using an axial technique, 0.5 pitch, 0.625-mm collimation, 350 maximal mA, 120 kVp (16-section) or 40- to 140-kVp spectral beam (64-section), 22-cm FOV, and 80–100 mL of iodinated contrast material administered by power injector at 4–5 mL per second into an antecubital vein by using SmartPrep (GE Healthcare), a semiautomated bolus tracking technique.
MRA examinations were performed on either 1.5T or 3T scanners (Symphony 1.5T, Skyra 3T, or Trio 3T; Siemens, Erlangen, Germany) by using standard arterial time-of-flight sequences provided by the vendor.
DSA was performed by using a dedicated biplanar neuroangiographic unit (Axiom Artis; Siemens) with transfemoral arterial access and intravenous conscious sedation. All DSA examinations included biplanar intracranial images after selective catheterization and contrast injection of both external carotid arteries and ICAs and at least 1 vertebral artery. Standard anteroposterior, lateral, and at least 2 oblique views of each vessel injected were obtained as part of our routine imaging protocol. In cases in which reflux opacification of the contralateral vertebral artery and PICA was not achieved from a given vertebral artery injection, we catheterized the contralateral vertebral or subclavian artery for imaging of the ipsilateral vertebral artery and PICA. Rotational angiography with 3D reconstructions was performed at the discretion of the interventional neuroradiologist but is not part of the routine imaging protocol at our institution.
Image Analysis
The NCCT examinations were independently reviewed by 2 experienced interventional neuroradiologists to determine the Fisher grade and pattern of SAH, categorized as diffuse, perimesencephalic, or peripheral sulcal. Perimesencephalic SAH was defined as SAH located mainly within the interpeduncular, prepontine, premedullary, ambient, and/or quadrigeminal plate cisterns without extension to the ventricular system, as defined by van Gijn et al.36
The DSA examinations were reviewed by 2 experienced interventional neuroradiologists to determine the presence of a causative vascular abnormality for the SAH. Differences in reader interpretation for the SAH pattern in the NCCT and the presence of a causative vascular abnormality in the catheter angiograms were adjudicated by consensus. Treatment decisions were reached by consensus of a panel comprising experienced interventional neuroradiologists and neurologic surgeons.
Medical Record Review
Medical records were reviewed for patient age, sex, family history of cerebral aneurysms, smoking history, admission Hunt and Hess scale, length of intensive care unit stay, and length of hospital stay.
Statistical Analysis
Statistical analysis was performed using the MedCalc, Version 11.1, software package (MedCalc Software, Mariakerke, Belgium). Interobserver agreement for the SAH-pattern categorization was determined with the κ statistic. A P value ≤ .05 was considered statistically significant.
Results
From January 1, 2007, until December 31, 2011, a total of 302 patients presented to our institution with nontraumatic SAH. Of these, 55 patients underwent an initial noninvasive neurovascular examination that was negative for a causative vascular abnormality (18.2%), comprising the patient cohort of this study. The initial examination was a CTA in 47 patients (85.5%) and an MRA in 8 patients (14.5%). Mean patient age was 58.2 years (median, 58 years; range, 25–88 years). Twenty-eight patients were men (50.9%), and 27 were women (49.1%). The mean length of intensive care unit stay was 7.7 days (median, 5 days; range, 0–34 days). The mean length of the hospital stay was 11.3 days (median, 9 days; range, 1–34 days). The On-line Table summarizes the clinical and radiologic characteristics of the patient cohort.
Thirty-three patients had diffuse SAH (60%), 11 patients had perimesencephalic SAH (20%), and 11 patients had peripheral sulcal SAH (20%). No patients with CSF xanthochromia were present in our cohort. Interobserver agreement for the categorization of SAH on the NCCT was excellent (κ = 0.86; 95% CI, 0.84–0.88). Of note, 6 of the 8 MRAs (75%) were performed in patients presenting with peripheral sulcal SAH, and 1 patient with diffuse SAH had an MRA performed first because of a known allergy to iodinated contrast material requiring premedication.
The mean time interval between the initial noninvasive neurovascular examination and the first DSA examination was 0.9 days (median, 1 day; range, 0–7 days). The first DSA examination demonstrated a causative vascular lesion for the SAH in 5 patients (9.1%), 4 of whom had diffuse SAH (yield of 12.1%) and 1 of whom had peripheral sulcal SAH (yield of 9.1%). The vascular lesions identified were 2 DAVFs (Fig 1), 1 pial cerebellopontine angle AVM with a 2-mm feeding artery aneurysm located in the internal auditory canal (Fig 2), a 2-mm blister ICA aneurysm (Fig 3), and a case of vasculopathy due to reversible cerebral vasoconstriction syndrome in a patient with peripheral sulcal SAH (Fig 4). One of the DAVFs and the blister ICA aneurysm were treated with endovascular embolization; the other DAVF was treated with radiosurgery alone. The pial AVM was treated with endovascular embolization of the feeding artery aneurysm followed by radiosurgery of the AVM nidus, and the case of vasculopathy was treated with cessation of the inciting medication. No causative vascular lesions were found in patients with perimesencephalic SAH in the first DSA examination.
A second DSA examination was performed in 32 patients (58.2%), including 23 of the 29 patients with diffuse SAH who had a negative first DSA examination (79.3%), 7 of the 11 patients with perimesencephalic SAH (63.6%), and 2 of the 10 patients with peripheral sulcal SAH who had a negative first DSA examination (20%). The mean time interval between the initial noninvasive neurovascular examination and the second DSA examination was 12.1 days (median, 9 days; range, 4–69 days). The second DSA examination demonstrated a causative vascular abnormality in 1 patient with diffuse SAH (yield of 4.3%). This lesion was a 2-mm anterior communicating artery aneurysm, which was treated with endovascular embolization (Fig 5). No causative vascular lesions were found in patients with perimesencephalic or peripheral sulcal SAH in the second DSA examination.
A third DSA examination was performed in 5 patients (9.1%), all with diffuse SAH. The mean time interval between the initial noninvasive neurovascular examination and the third DSA examination was 29.4 days (median, 32 days; range, 12–53 days). No causative vascular lesions were found in the third DSA examination.
Overall, DSA demonstrated a causative vascular lesion for the SAH in 6 patients (yield of 10.9%), 5 of whom had diffuse SAH (yield of 15.2%) and 1 of whom had peripheral sulcal SAH (yield of 9.1%). No causative vascular lesions were found in patients with perimesencephalic SAH.
Retrospective review of the initial CTA and MRA showed that in 1 patient, the causative vascular lesion was evident but not recognized by the initial reader, and in the other 5 patients, the vascular lesion was not evident.
Discussion
The frequency of negative initial CTA and MRA in patients with SAH in our study, 18.2%, is similar to that reported by Agid et al29 in patients with SAH initially evaluated with CTA (22.1%). These findings suggest that though CTA is a very useful initial noninvasive diagnostic tool for the evaluation of this patient population, there are still a significant minority of patients who will require further evaluation with DSA due to a negative initial noninvasive neurovascular examination.
We found that the overall yield of DSA in patients with SAH and negative initial neurovascular examinations was 10.9%, with a higher yield in patients with diffuse (15.2%) and peripheral (9.1%) SAH compared with patients with perimesencephalic SAH (0%). The overall yield of our study is within the range of past studies examining the yield of repeat DSA in patients with SAH and a negative initial DSA examination (0%–14%17,18,27,30,31), but it is higher than that in the previous study by Agid et al examining the yield of DSA in patients with SAH and a negative initial CTA (4.2%). The difference in overall yield of DSA between our study and that of Agid et al29 is likely explained by the larger proportion of patients with perimesencephalic SAH in their patient cohort (48.2%) compared with that in our study (20%). Indeed, the yield of DSA in the different SAH patterns is similar in the study of Agid et al and our study: 10% and 15% for diffuse SAH, 17% and 9% for peripheral sulcal SAH, and 0% for perimesencephalic SAH in both studies. Similarly, Cruz et al33 also found the yield of DSA in a cohort of 43 patients with perimesencephalic SAH and a negative initial CTA to be 0%. These results suggest that performing conventional angiography after a negative CTA may not be necessary in patients with perimesencephalic SAH. However, a recent study by Delgado Almandoz et al30 reported finding a causative cerebral aneurysm at repeat DSA performed 7 days after presentation in 1 of 29 patients with perimesencephalic SAH who had negative initial DSA and CTA examinations (yield of 3.4%). The combined sample size of patients with perimesencephalic SAH and negative initial neurovascular examinations in these 4 studies is modest (176 patients), and future prospective studies with larger sample sizes may be needed to definitively determine when to stop imaging this specific patient population.
In our study, a second DSA examination performed 7 days after the initial noninvasive examination yielded positive results only in patients with diffuse SAH (yield of 4.3%), which was similar to that reported by Delgado Almandoz et al30 (yield of 5.1%) but lower than that reported by Maslehaty et al31 (yield of 10.8%) in patients with nonperimesencephalic SAH. In both the present study and that of Delgado Almandoz et al, a third DSA examination did not reveal any additional underlying neurovascular abnormalities. These results suggest that patients with diffuse SAH would benefit from a second DSA examination performed approximately 7 days after the initial neurovascular examination but not from a third DSA examination thereafter.
We found that the causative vascular abnormalities demonstrated by DSA in our cohort were a combination of DAVFs, small pial AVMs, small aneurysms, and vasculopathy, which were not preferentially localized to any particular blood vessel or region of the skull base. This is in contradistinction to the previous study by Agid et al,29 in which small aneurysms and vasculopathy encompassed all of the vascular lesions identified by DSA but no DAVFs or AVMs were found. Our results suggest that detailed evaluation of the entire neurovascular tree, including the external carotid artery branches, is important to confidently exclude a vascular lesion as the SAH etiology in patients with negative initial noninvasive neurovascular examinations.
The limitations of our study are the lack of rotational angiography with 3D reconstructions in all catheter angiograms and the modest sample size.
Conclusions
DSA is a valuable tool in the evaluation of patients with diffuse and peripheral sulcal SAH who have a negative initial noninvasive neurovascular examination, demonstrating a causative vascular lesion in 15.2% and 9.1% of patients, respectively.
Acknowledgments
We acknowledge Sandee K. Verootis, Radiology Department, Abbott Northwestern Hospital, for her contribution in the data collection for this study.
Footnotes
Disclosures: Josser E. Delgado Almandoz—UNRELATED: Travel/Accommodations/Meeting Expenses Unrelated to Activities Listed: Covidien/ev3. Benjamin M. Crandell—UNRELATED: Payment for Lectures (including service on Speakers Bureaus): ev3, Comments: balloon-remodeling techniques course. David E. Tubman—UNRELATED: Consultancy: Covidien/ev3, MicroVention, Lake Region Medical, Payment for Lectures (including service on Speakers Bureaus): Covidien/ev3.
No external sources of funding were used for the completion of this study.
Paper previously presented in part at: International Stroke Conference, February 1–2, 2012; New Orleans, Louisiana; and in whole at: 50th Annual Meeting of the American Society of Neuroradiology and the Foundation of the ASNR Symposium, April 21–26, 2012; New York, New York.
References
- Received June 4, 2012.
- Accepted after revision July 9, 2012.
- © 2013 by American Journal of Neuroradiology